Blurbs

Analysts Are Bullish on These Healthcare Stocks: Biolase (BIOL), Supernus Pharmaceuticals (SUPN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biolase (BIOLResearch Report), Supernus Pharmaceuticals (SUPNResearch Report) and Intra-Cellular Therapies (ITCIResearch Report) with bullish sentiments.

Biolase (BIOL)

Colliers Securities analyst Kyle Bauser reiterated a Buy rating on Biolase today and set a price target of $2.00. The company’s shares closed last Monday at $0.34, close to its 52-week low of $0.31.

According to TipRanks.com, Bauser ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.7% and a 36.8% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Chembio Diagnostics, and Semler Scientific.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biolase with a $2.00 average price target, representing a 506.1% upside. In a report issued on January 10, Maxim Group also reiterated a Buy rating on the stock with a $2.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Supernus Pharmaceuticals (SUPN)

Jefferies analyst David Steinberg maintained a Buy rating on Supernus Pharmaceuticals today and set a price target of $44.00. The company’s shares closed last Monday at $29.14.

According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 7.9% and a 47.4% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Pacira Pharmaceuticals, and Sol-Gel Technologies.

Supernus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $40.50.

Intra-Cellular Therapies (ITCI)

In a report issued on January 21, Andrew Tsai from Jefferies maintained a Buy rating on Intra-Cellular Therapies, with a price target of $85.00. The company’s shares closed last Monday at $44.34.

According to TipRanks.com, Tsai is a 1-star analyst with an average return of -0.5% and a 43.2% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Relmada Therapeutics, ATAI Life Sciences, and Athira Pharma.

Currently, the analyst consensus on Intra-Cellular Therapies is a Strong Buy with an average price target of $62.71, a 48.6% upside from current levels. In a report issued on January 6, RBC Capital also maintained a Buy rating on the stock with a $55.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BIOL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos